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Abstract
Background: Serologic tests for HIV infection in infants less than 18 months do not differentiate exposure and
infection since maternally acquired IgG antibodies may be detected in infants. Thus, the gold standard for diagnosis
of HIV-1 infection in infants under the age of 2 years is DNA or reverse transcriptase polymerase chain reaction.
There is an urgent need to evaluate alternative and cost effective laboratory methods for early diagnosis of infant
HIV-1 infection as well as identifying infected infants who may benefit from cotrimoxazole prophylaxis and/or
initiation of highly active antiretroviral therapy.
Methods: Whole blood was collected in EDTA from 137 infants aged 0 to 18 months. DNA polymerase chain
reaction was used as the reference standard for diagnosis of HIV-1 infection. T-cell subset profiles were
determined by flow cytometry.
Results: Seventy-six infants were DNA PCR positive while 61 were negative. The median CD4 counts of PCR
negative infants were significantly higher than those of the PCR positive infants, p < 0.001. The median CD4/CD8
ratio and the %CD4 of the PCR positive infants were both significantly lower than those of the negative infants,
p < 0.001. The CD4/CD8 ratio had a >98% sensitivity for diagnosis of HIV-1 infection and a specificity of >98%.
Conclusion: The CD4/CD8 ratio appears useful in identifying HIV-infected infants. The development of lower
cost and more robust flow cytometric methods that provide both CD4/CD8 ratio and %CD4 may be cost-
effective for HIV-1 diagnosis and identification of infants for cotrimoxazole prophylaxis and/or highly active
antiretroviral therapy.
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Background
Endemic HIV infection, in sub-Saharan Africa, where in
many countries more than 20% of pregnant women are
HIV seropositive leads to a diagnostic problem in the eval-
uation of their infants. Without intervention, more than
25% of infants born to seropositive women will acquire
HIV infection in the first year of life. HIV testing with
enzyme immunoassay-based rapid tests have expanded
capacity to identify seropositive women and provide
interventions, but even with single dose Nevirapine and
other antiretrovirals, infection of infants still exceeds 10%
in the first year of life. Serologic tests for HIV do not accu-
rately identify those infants who have acquired infection
within the first 18 months of life because of transplacen-
tally acquired maternal IgG antibodies. As antimicrobial
and antiviral interventions are developed to reduce mor-
bidity and mortality, among infants born to seropositive
women, the early diagnosis of infection is increasingly
important. The gold standard for diagnosis of HIV-1 infec-
tion in infants under the age of 2 years is DNA polymerase
chain reaction (PCR) or reverse transcriptase (RT)-PCR [1-
3]. With the increasing availability of single dose nevirap-
ine for prevention of mother-to-child transmission
(MTCT) of HIV [4] and generic antiretroviral drugs for
treatment of AIDS in resource-poor countries, there is an
urgent need to develop alternative laboratory methods for
early diagnosis of infant HIV-1 infection as well as identi-
fying infants who meet the criteria for commencing cotri-
moxazole prophylaxis and/or initiation of ARV therapy.
The World Health Organization (WHO) recommends ini-
tiation of highly active antiretroviral therapy (HAART) in
HIV-seropositive infants under the age of 18 months, who
have WHO Pediatric Stage III disease and CD4 percentage
(%CD4) <20% in resource-poor countries where %CD4
are available but virologic tests (DNA PCR, RT-PCR or
immune-complex dissociated p24 antigen) for confirma-
tion of HIV infection are not available [5]. Thus, in infants
under the age of 18 months, a single laboratory test that
can identify both HIV-infection and provide %CD4, two
important parameters for decision-making in initiating
HAART, may be useful. Infants who are positively identi-
fied as HIV-infected and meet clinical criteria are likely to
benefit from HAART.
Immunological changes in HIV-1 infection include a
decrease in CD4+ cells, a transient increase in CD8+ cells,
total lymphocytes and inversion of the CD4/CD8 ratio
[6,7]. As HIV infection progresses, the CD4+ cells decline,
while the CD8+ cells which may remain at high levels for
long periods, eventually decrease but not to baseline lev-
els. Since in healthy children the CD4+ and CD8+ cells
account for 60% and 30% of the T lymphocytes respec-
tively, a normal CD4/CD8 ratio should always be >1.0.
Thus, in HIV-1 infection where there is a decrease in CD4+
cells and an increase in CD8+ cells, the reversal of the
CD4/CD8 to <1.0 should in theory be useful for diagnosis
of HIV-1 infection.
Certain flow cytometers when used in tandem with a hae-
matological analyzer can provide absolute CD4+  cell
counts, their percentages as well as the CD4/CD8 ratio.
The use of the ratio in combination with %CD4, may lead
to a timely identification of infected infants, who meet the
WHO criteria for initiation of CTX prophylaxis and/or
ARV therapy. While the infrastructure needed to conduct
flow-cytometric analyses of HIV infection are still largely
confined to a few centers, an increasing number of point
of care diagnostic testing systems, inexpensive methods to
measure CD4 cells are currently in development. These
include the development and evaluation of simplified
volumetric flow cytometric methods using a low cost flow
cytometer that can be powered from a car battery or by
solar panels (Cyflow SL, Partec, Munster, Germany) by
Cassens and colleagues [8,9] and modification of a com-
mercially available 4-parameter flow cytometer, Luminex
100 (Luminex, Austin Texas, USA) to a compact portable
prototype instrument that can operate with a 12-volt
rechargeable battery [10]. Furthermore, use of generic
CD4, CD8 and CD45 fluorescence-conjugated mono-
clonal antibodies can reduce the cost of determining T cell
subset profile even when employing standard flow cytom-
eters [10,11].
The main objective of the current study was to evaluate
the CD4/CD8 ratio for diagnosis of subtype C HIV-1
infection in infants under the age of 2 years among infants




The infant specimens used in this study were obtained
from two independent prospective studies; the short
course zidovudine (AZT) and Pediatric AIDS Clinical def-
inition (PACD). The Medical Research Council and the
Institutional Ethics Committees approved both studies
and present study. The infants included in the study were
under the age of 2 years. All the infants were breastfeeding
at the time of specimen collection.
Infants who were followed in the short course AZT study
aimed at preventing MTCT were enrolled between May
2001 and June 2002. In the AZT study, mothers received
short course AZT starting at 36 weeks gestation and
throughout labor. Their infants received AZT for 7 days.
In the PACD study, hospitalized children aged between 2
months and 18 months were prospectively enrolled into
the study, between July 2002 and July 2003, followingJournal of Translational Medicine 2005, 3:6 http://www.translational-medicine.com/content/3/1/6
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informed consent from their mothers. The mothers of
these children did not receive antiretroviral therapy for
prevention of MTCT nor for HIV disease. The PACD study
is a hospital based analytical cross-sectional survey. Labo-
ratory specimens were obtained once from each subject.
Children presenting in the moribund state, requiring
immediate resuscitation or those with known HIV status
or those whose mothers/guardians refused to sign the
informed consent were excluded from the study. The
objective of the PACD study is to identify clinical symp-
toms, associated with HIV-1 infection in infants under the
age of 18 months, which may be used in the absence of
laboratory tests, for HIV-1 diagnosis.
Blood collection and processing
A total volume of 2 ml whole blood was collected in eth-
ylenediamine tetraacetic acid from each of the 137 infants
in the short course AZT and the PACD studies. The whole
blood was then aliquoted into two tubes (500 microlitres
in each) for determination of T cell subset profiles, and
the second for DNA PCR and the rest centrifuged at 200 g
to obtain plasma, which was stored at -80°C.
The laboratory tests described below were conducted in a
blind fashion.
Flow cytometry analysis
T cell subset profiles were determined by flow cytometry
using a Coulter Epics XL equipped with System II software
(Beckman Coulter, Miami, Florida, USA) within 4 hours
of blood collection. This flow cytometer was run, in a
double platform setting where the absolute counts for
both white blood cells and lymphocytes were obtained on
a Celldyn 3500R haematological analyzer (Abbott,
GmbH, Germany). Then from the combined results, the
absolute CD4+ and CD8+ cell counts, CD4/CD8 ratios, as
well as the %CD4 and %CD8 values among lymphocytes
were automatically calculated.
DNA PCR analysis
DNA PCR Roche amplification assay version 1.5 (Roche
Diagnostics, Branchburg, NJ, USA) was employed as the
reference standard for diagnosis of infant HIV-1 infection
status. DNA extraction, amplification and detection were
performed and results interpreted following the manufac-
turer's instructions (Roche Diagnostics, Branchburg, NJ,
USA) as we previously described [12,13].
Infant grouping
Reference ranges of T cell subset profiles for infants and
children are usually stratified by age as <12 months, 1 to
5 years and 6–12 years. In the current study, in addition to
overall evaluation of samples obtained from all the
infants aged 0 to 18 months, the evaluated parameters
were also compared based on infant age groups 0–11, and
12–18 months.
Statistical Analysis
Diagnostic tests (sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV) and test effi-
ciency (TE) with 95% confidence interval) were used to
assess the assay under evaluation with DNA PCR as the
reference standard. A MTCT prevalence rate of 30.7%
(based on the current rate in Zimbabwe) was used in the
calculations of PPV and NPV. Sensitivity was defined as
the percentage of reference standard HIV positive samples
found reactive by assay under evaluation. Specificity was
defined as the percentage of reference standard HIV-nega-
tive samples that were negative by the assay under evalua-
tion. TE refers to the overall ability of a test to correctly
identify all positives and negatives (the absence of false
positives and false negatives). It is a combination of the
sensitivity and the specificity of an assay and gives an idea
of the total effectiveness of the assay. PPV was defined as
the probability that a specimen had CD4:CD8 ratio less
than 1 when the test was DNA PCR positive. NPV was
defined as the probability that a specimen does not have
a CD4:CD8 ratio ≥ 1 when the test was DNA PCR
negative.
Comparisons of T cells between infected and uninfected
infants were done using non-parametic equivalent of the
T-test (Kruskal-Wallis test). P values less than 0.05 were
considered statistically significant.
Results
Of the 137 infant specimens tested using DNA PCR, 76
were HIV-1 positive and 61 were HIV-1 negative. The 76
PCR positive infants included 9 infants who had evidence
of in utero transmission as determined by serial DNA PCR
of birth and subsequent samples tested in longitudinal
short course AZT MTCT studies (Zijenah et al, unpub-
lished data).
T cell subset of infected and uninfected infants
T lymphocyte subset profiles were performed for the 137
infants who had whole blood specimens for flow cytome-
try. The median age of these infants at specimen collection
was 5.5 months (Interquartile Range [IQR]: 3–13) and 8.0
months (IQR: 4–14) for HIV infected and uninfected
respectively (p = 0.08). As expected, the median CD4+ cell
counts of PCR negative infants were significantly higher
than those of the PCR positive infants, p < 0.001 (Table 1).
Inversely, the median CD8+ cell counts were significantly
higher among PCR positive infants than PCR negative
infants, p < 0.001 (Table 1). The median CD4/CD8 ratio
of the PCR positive infants (0.4, IQR: 0.3–0.6) was signif-
icantly lower than that of the PCR negative infants (1.8,Journal of Translational Medicine 2005, 3:6 http://www.translational-medicine.com/content/3/1/6
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IQR: 1.4–2.3), p < 0.001. The median %CD4 of PCR
positive infants was also significantly lower than that of
PCR negative infants, p = < 0.01 (Table 1).
DNA PCR versus CD4/CD8 ratio
Seventy-five infants of the 76 PCR positive group (98.7%)
had CD4/CD8 ratio <1 while 60 infants of the 61 who
were PCR negative had CD4/CD8 ratio ≥ 1. All the 9
infants infected in utero had a CD4:CD8 ratio less than 1.
Their median CD4/CD8 ratio was similar to that of the
rest of the PCR positive babies (0.4; IQR: 0.3–0.6), albeit
the numbers are too small for statistical significance con-
siderations. The infant (aged 11 months at specimen col-
lection) who was DNA PCR positive with a CD4/CD8
ratio of 1.1 was from the PACD study. The PCR negative
infant (aged 4 months at specimen collection) with a
CD4/CD8 ratio of 0.3 was also from the PACD cohort.
The overall sensitivity and specificity of the CD4/CD8
ratio were 98.7% (95% CI: 96.1–100 and 98.3% (95%
Confidence Interval (CI): 95.1–100) respectively with
PPV and NPV of 96.3% and 99.4% respectively and a test
efficiency of 98.5% (95% CI: 96.5–100) (Table 2). Com-
parison of all the evaluated parameters between the 0–11
and 12–18 months infant age groups showed that the
95% CI overlap between the groups which implies no sta-
tistically significant difference in these two age groups.
Discussion
In resource-poor countries, the major constraint in the use
of DNA PCR for diagnosis of HIV-1 infection in infants
under the age of 18 months is the cost of the equipment
and the reagents. In addition, highly trained laboratory
personnel and stringent quality assurance measures are
needed to run this assay for routine diagnosis of HIV
infection in infants.
In Zimbabwe, enzyme linked immunosorbent assay
(ELISA) is routinely performed in both public and private
laboratories for diagnosis of various infections including
HIV-1. However, because of the transplacental transfer of
maternal IgG antibodies, which may persist in infants for
up to 18 months, ELISA is not suitable for diagnosis of
HIV-1 infection in these infants. Therefore alternative
methods are needed for this purpose. In addition, both
public and private laboratories have flow cytometers or
FACSCount machines for enumeration of T cell subset
profile and automated haematological analysers for rou-
tine full blood counts with differential. With this equip-
ment available in the country we evaluated the CD4/CD8
ratio as an alternative diagnostic test for infant HIV-1
infection.
In our investigation we used Epics XL Coulter flow cytom-
eter equipped with System II software (Beckman Coulter,
Table 1: T cell subset profile of HIV-1 infected and uninfected infants
PCR Positive (n = 76) PCR Negative (n = 61) P valuea
Median age (months) 5.5 (IQR: 3–13) 8 (IQR: 4–14) 0.08
Median CD4+(cells/µL) 521.5 (IQR: 323–805) 1356 (IQR: 916–1769) <0.001
Median CD8+(cells/µL) 1302.5 (IQR: 829–2054) 799 (IQR: 471–1020) <0.001
Median CD4/CD8 ratio 0.4 (IQR: 0.3–0.6) 1.8 (IQR: 1.4–2.3) <0.001
Median %CD4 13.9 (IQR: 9.2–19.1) 29.9 (IQR: 25.3–34.5) <0.001
Median %CD8 31.3 (IQR: 22.3–42.9) 18.4 (IQR: 14.2–21.5) <0.001
Abbreviations: PCR, polymerase chain reaction; n, number tested; P valuea for statistical significance between group medians was estimated using 
the Kruskal-Wallis test.
Table 2: Evaluated parameters for CD4/CD8 ratio for the three infant age groups using DNA PCR as reference standard
0–18 months infant age group 
(n = 137)
0–11 months infant age group 
(n = 95)
12–18 months infant age group 
(n = 42)
%Sensitivity 98.7 (CI: 96.1–100) 98.2 (CI: 94.7–100) 100 (CI: 100–100)
%Specificity 98.4 (CI: 95.2–100) 97.5 (CI: 92.7–100) 100 (CI: 100–100)
%PPV 96.4 94.6 100
%NPV 99.4 99.2 100
%TE 98.5 (CI: 96.5–100) 97.9 (CI: 95.0–100) 100 (CI: 100–100)
Abbreviations: n, number tested; NPV, negative predictive value; PPV, positive predictive value; TE, test efficiency.Journal of Translational Medicine 2005, 3:6 http://www.translational-medicine.com/content/3/1/6
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Miami Florida, USA) for the following reasons. With this
instrument, CD4/CD8 ratios can be conveniently
obtained. In addition, when used in double platform set-
ting tandem with a haematological analyzer, the results
also show absolute CD4+ cell counts and both %CD4 and
%CD8 values among lymphocytes. The %CD4 value
among lymphocytes is the recommended parameter for
analyzing pediatric samples, as absolute counts for infants
are age sensitive and variable. A simpler single platform
system such as the FACScount (Becton-Dickinson Immu-
nocytometry Systems, San Jose, CA, USA), is not fully
suited for pediatric work as it provides CD4+, CD8+, CD3+
T lymphocyte counts and CD4/CD8 ratio but %CD4 are
not available. Of note, %CD4 expressed among CD3+ T
lymphocytes, is a different parameter from the customary
%CD4 expressed among lymphocytes. The %CD4
expressed among lymphocytes and not the %CD4
expressed among CD3+ T lymphocytes is recommended
for decision making to initiate ARV therapy in children
under the age of 18 months [5].
In Zimbabwe, CD4+ cell count, is less expensive than PCR
and may provide additional information of value to the
clinician with respect to prognosis, and the need for
prophylaxis and treatment. Optimal flow cytometry for
determination of T cell subset profile, offers the added
advantage that CD4/CD8 ratio will determine the infec-
tion status of the infant while the % CD4 will provide
information on decision-making for commencement of
HAART.
Overall, the CD4/CD8 ratio had a ≥ 98% sensitivity for
diagnosis of infant HIV-1 infection and a specificity ≥
98%. Both sensitivity and specificity were 100% for
infants in the 12–18 months age group. Interestingly, in
parallel studies performed in 250 HIV-1 seropositive
adults, 249 had a CD4/CD8 ratio of <1. The CD4/CD8
ratio of the one patient was 1 at enrollment and has
remained so for over one year.
When interpreting our data, it is important to note that
normal T cell subset values among African children differ
from those of other populations [14-16]. A study in
Guinea Bissau [16], reported that Guinean children under
the age of 2 years had lower %CD4 and CD4/CD8 ratios
and higher %CD8 when compared to their counterparts
from developed countries. Interestingly, girls had higher
CD4/CD8 ratios and lower %CD8 than boys. In our
study, there were no statistically significant differences in
absolute T cells, or percentages or CD4/CD8 ratio
between boys and girls (Table 3 "refer to Additional file
1").
A very few studies in Africa have compared T cell subset
profiles between HIV-1 infected and uninfected infants
under the age of 2 years [14,17]. Moodley and colleagues
in South Africa reported that the most marked changes in
lymphocyte subset of HIV-1 infected children aged
between 3 and 15 months were a lower %CD4 and higher
%CD8 relative to uninfected infants [17]. In addition,
CD4/CD8 ratio was a good predictor of poor clinical out-
come at 3 months. The authors concluded that CD4/CD8
ratio and %CD4 among lymphocytes are reliable markers
of HIV-1 infection in an African pediatric population. Fur-
thermore a raised CD8+ cell count rather than a CD4+ cell
count was a more specific prognostic marker of disease
progression in HIV infected children.
Embree and colleagues, in Kenya, also reported that HIV-
1 infected children had lower %CD4 and higher %CD8 by
3 months when compared to uninfected children [13].
The authors concluded that %CD4 and %CD8 among
lymphocytes could be useful as an adjunct in HIV-1
diagnosis.
The two African studies mentioned above, have docu-
mented the clinical value of %CD4, CD4/CD8 ratio and
CD8 counts in HIV-1 infection in infants.
In summary, the CD4/CD8 ratio may be useful in identi-
fying infected infants while %CD4 will identify infants
who may benefit from cotrimoxazole prophylaxis and/or
initiation of HAART, and for management of HIV-infected
infants in developing countries in general. We thus pro-
pose use of flow cytometry, where available, as a point of
care diagnostic tool for ill infants admitted to hospitals
with clinical symptoms suggestive of HIV infection and/or
AIDS.
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